Study of Quadruple Therapy With Eltrombopag for Chronic Hepatitis C

Inclusion Criteria: * Male and female patients at least 18 years of age. * Require a platelet count below 75 x 10\^9 /L at time of screening. * The patients must meet the eligibility criteria for all drugs involved. * Only genotype 1 (a, b, indeterminate, or mixed). * Confirmed history of chronic hepatitis C. * Cirrhotic patients will be included. * Liver imaging within 1 year to exclude hepatocellular carcinoma (HCC) is required in patients with cirrhosis. * Patients without evidence of cirrhosis but meeting platelet criteria will also be admitted to study. * Subjects must be able to provide informed consent, comply with drug administration instructions, and be able to complete each study visit. * Ability to cover costs of ribavirin, interferon, and boceprevir will also be required. * Female subjects are eligible if: Non-pregnant, non-childbearing potential, or of childbearing potential and willing to perform complete abstinence or correctly use a form of birth control during intercourse \[barrier method, intrauterine device, hormonal therapy, or surgical sterilization in females or male partner\]. They must also be willing to have pregnancy tests performed every 4- weeks until 6 months after completion of ribavirin. * Male study participants must agree to use a condom and their female partner must partake in one of the contraceptive methods discussed above until 6 months after completion of ribavirin therapy. Exclusion Criteria: * A history of chronic infection (i.e., HIV or HBV) or a previous organ transplantation. * A history of a platelet disorder. * A poorly controlled underlying medical illness (i.e., diabetes, hypertension, coronary artery disease, congestive heart failure, etc.). * Any contraindication to any study drugs as mentioned in their respective prescribing information. * Patients with decompensated cirrhosis defined as current evidence for ascites, encephalopathy, infection or variceal bleeding. All patients should be considered Child-Pugh Class A. * Patients with aminotransferase levels ≥ 500 IU/L will be excluded on presumption of another active liver disease. * Patients must not be pregnant or nursing. * The study physician maintains the right to exclude a patient for a medical condition not listed above or based off laboratory values indicating chronic disease discovered at screening. * Patients with eye disease may be excluded from this study if the ophthalmologist does not recommend treatment. * Subjects with known hypersensitivity reactions (such as Stevens-Johnson syndrome, toxic, epidermal necrolysis, and erythema multiforme to ribavirin) to study drugs or any component of the products. * Subjects with autoimmune hepatitis, hemoglobinopathies (e.g., thalassemia major, sickle-cell anemia), creatinine clearance less than 50 mL/min. * Co-administration of drugs that are highly dependent on CYP3A4/5 for clearance and CYP3A4/5 inducers (See Table 2 in boceprevir prescribing information).